MX2021011613A - Receptores de células t de mage a4. - Google Patents
Receptores de células t de mage a4.Info
- Publication number
- MX2021011613A MX2021011613A MX2021011613A MX2021011613A MX2021011613A MX 2021011613 A MX2021011613 A MX 2021011613A MX 2021011613 A MX2021011613 A MX 2021011613A MX 2021011613 A MX2021011613 A MX 2021011613A MX 2021011613 A MX2021011613 A MX 2021011613A
- Authority
- MX
- Mexico
- Prior art keywords
- tcr
- mage
- cell receptors
- polypeptide
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un receptor de células T aislado (TCR) específico para MAGE-A4 y un polipéptido que comprende una porción funcional del TCR. También están implicados un complejo de TCR multivalente, un ácido nucleico que codifica para un TCR, una célula que expresa el TCR y una composición farmacéutica que comprende el TCR. La invención también se refiere al TCR para su uso como un medicamento, en particular al TCR para uso en el tratamiento de cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19165387.2A EP3714941A1 (en) | 2019-03-27 | 2019-03-27 | Mage-a4 tcrs |
| PCT/EP2020/058779 WO2020193767A1 (en) | 2019-03-27 | 2020-03-27 | Mage a4 t cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011613A true MX2021011613A (es) | 2021-12-15 |
Family
ID=66000958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011613A MX2021011613A (es) | 2019-03-27 | 2020-03-27 | Receptores de células t de mage a4. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12344654B2 (es) |
| EP (3) | EP3714941A1 (es) |
| JP (2) | JP7590982B2 (es) |
| KR (1) | KR20210150440A (es) |
| CN (2) | CN118580335A (es) |
| AU (1) | AU2020249598A1 (es) |
| BR (1) | BR112021019066A2 (es) |
| CA (1) | CA3134076A1 (es) |
| CL (1) | CL2021002491A1 (es) |
| CO (1) | CO2021012587A2 (es) |
| DK (1) | DK3946621T3 (es) |
| EA (1) | EA202192327A1 (es) |
| ES (1) | ES3037919T3 (es) |
| FI (1) | FI3946621T3 (es) |
| HR (1) | HRP20250993T1 (es) |
| HU (1) | HUE073008T2 (es) |
| IL (1) | IL286569A (es) |
| LT (1) | LT3946621T (es) |
| MX (1) | MX2021011613A (es) |
| PL (1) | PL3946621T3 (es) |
| PT (1) | PT3946621T (es) |
| RS (1) | RS67109B1 (es) |
| SG (1) | SG11202110171QA (es) |
| SI (1) | SI3946621T1 (es) |
| SM (1) | SMT202500298T1 (es) |
| WO (1) | WO2020193767A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| CN113366479A (zh) | 2018-12-14 | 2021-09-07 | 蓝鸟生物公司 | 二聚化剂调节的免疫受体复合物 |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| JP7723887B2 (ja) * | 2019-05-08 | 2025-08-15 | メディジーン イミュノテラピーズ ゲーエムベーハー | 操作されたｔ細胞 |
| US20230124640A1 (en) * | 2020-03-27 | 2023-04-20 | 2Seventy Bio, Inc. | T cell receptors |
| CN111647069B (zh) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | 一种改进的tcr及其应用 |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
| JP2024509910A (ja) | 2021-03-09 | 2024-03-05 | シーディアール－ライフ・アクチェンゲゼルシャフト | Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
| JP2025513801A (ja) | 2022-04-08 | 2025-04-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多部位受容体及びシグナル伝達複合体 |
| US20250382636A1 (en) | 2022-05-26 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
| CN119569851A (zh) * | 2023-09-05 | 2025-03-07 | 香雪生命科学技术（广东）有限公司 | 针对magea4的高亲和力tcr |
| EP4635976A1 (en) * | 2024-04-19 | 2025-10-22 | Medigene Immunotherapies GmbH | Constant uni-tabs |
| WO2025219541A1 (en) * | 2024-04-19 | 2025-10-23 | Medigene Immunotherapies Gmbh | Constant uni-tabs |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| NZ531208A (en) | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| EP2006376A1 (en) | 2007-06-21 | 2008-12-24 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| PT2895509T (pt) | 2012-09-14 | 2020-03-13 | Us Health | Recetores de células t que reconhecem mage-3 restrito a mhc de classe ii |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP2944652A1 (en) | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| CA3248123A1 (en) | 2015-01-31 | 2025-11-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| CR20180531A (es) * | 2016-04-08 | 2019-06-13 | Immunocore Ltd | Receptores de células t |
| HUE056433T2 (hu) * | 2016-04-08 | 2022-02-28 | Adaptimmune Ltd | T-sejt receptorok |
| EP3519433A1 (en) | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| KR20250040097A (ko) * | 2017-08-18 | 2025-03-21 | 그릿스톤 바이오, 인코포레이티드 | 공유된 항원을 표적화하는 항원-결합 단백질 |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| JP7723887B2 (ja) | 2019-05-08 | 2025-08-15 | メディジーン イミュノテラピーズ ゲーエムベーハー | 操作されたｔ細胞 |
-
2019
- 2019-03-27 EP EP19165387.2A patent/EP3714941A1/en not_active Withdrawn
-
2020
- 2020-03-27 CN CN202410548142.5A patent/CN118580335A/zh active Pending
- 2020-03-27 AU AU2020249598A patent/AU2020249598A1/en active Pending
- 2020-03-27 BR BR112021019066A patent/BR112021019066A2/pt unknown
- 2020-03-27 SG SG11202110171QA patent/SG11202110171QA/en unknown
- 2020-03-27 JP JP2021560302A patent/JP7590982B2/ja active Active
- 2020-03-27 US US17/441,861 patent/US12344654B2/en active Active
- 2020-03-27 PL PL20719942.3T patent/PL3946621T3/pl unknown
- 2020-03-27 RS RS20250809A patent/RS67109B1/sr unknown
- 2020-03-27 KR KR1020217035022A patent/KR20210150440A/ko active Pending
- 2020-03-27 EA EA202192327A patent/EA202192327A1/ru unknown
- 2020-03-27 DK DK20719942.3T patent/DK3946621T3/da active
- 2020-03-27 PT PT207199423T patent/PT3946621T/pt unknown
- 2020-03-27 SM SM20250298T patent/SMT202500298T1/it unknown
- 2020-03-27 MX MX2021011613A patent/MX2021011613A/es unknown
- 2020-03-27 EP EP25177671.2A patent/EP4631516A2/en active Pending
- 2020-03-27 LT LTEPPCT/EP2020/058779T patent/LT3946621T/lt unknown
- 2020-03-27 ES ES20719942T patent/ES3037919T3/es active Active
- 2020-03-27 CN CN202080039452.4A patent/CN114126716B/zh active Active
- 2020-03-27 FI FIEP20719942.3T patent/FI3946621T3/fi active
- 2020-03-27 EP EP20719942.3A patent/EP3946621B1/en active Active
- 2020-03-27 HR HRP20250993TT patent/HRP20250993T1/hr unknown
- 2020-03-27 WO PCT/EP2020/058779 patent/WO2020193767A1/en not_active Ceased
- 2020-03-27 SI SI202030648T patent/SI3946621T1/sl unknown
- 2020-03-27 HU HUE20719942A patent/HUE073008T2/hu unknown
- 2020-03-27 CA CA3134076A patent/CA3134076A1/en active Pending
-
2021
- 2021-09-22 IL IL286569A patent/IL286569A/en unknown
- 2021-09-24 CO CONC2021/0012587A patent/CO2021012587A2/es unknown
- 2021-09-24 CL CL2021002491A patent/CL2021002491A1/es unknown
-
2024
- 2024-11-15 JP JP2024199432A patent/JP2025024103A/ja active Pending
-
2025
- 2025-05-23 US US19/217,625 patent/US20250346648A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011613A (es) | Receptores de células t de mage a4. | |
| EA202092032A1 (ru) | Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| WO2018132739A3 (en) | T cell receptors that bind to ny-eso-1 and methods of use thereof | |
| WO2020086647A8 (en) | Ny-eso-1 t cell receptors and methods of use thereof | |
| CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
| CR20200287A (es) | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado | |
| MX2024005677A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| MX2015003061A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. | |
| CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
| EP4032544A3 (en) | Novel t cell receptors and immune therapy using the same | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| AR112902A1 (es) | Receptores de células t restringidas a hla de clase ii contra ras mutado | |
| WO2016026854A3 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| MX2016015383A (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| CL2021001794A1 (es) | Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227) | |
| PH12015502125B1 (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
| MX2016013159A (es) | Expresion transgenica regulada por farmaco. | |
| EA202192726A1 (ru) | Magea1-специфические т-клеточные рецепторы и их использование | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| MX2023003371A (es) | Receptores de células t específicos de mage-a3 y su uso. | |
| FI3380115T3 (fi) | Peptidejä piwil1:stä | |
| WO2016077525A3 (en) | Human anti-thyroglobulin t cell receptors | |
| BR112019011461A2 (pt) | terapia celular à base de nk melhorada |